Empagliflozin 98%

Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment.

This quest, for healing the world, drives our performance and helps us move towards our Vision.

We are present across varied therapies such as antituberculosis, antimalarials, antiretrovirals, antibacterials, antidiabetics, antihypertensives and antiasthmatics. We are also known for the number of WHO pre-qualified medicines, used in the treatment of HIV/AIDS, Malaria, Tuberculosis (TB) and opportunistic infections.

We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers.